Amedisys, Inc.: Michael North, Chief Information Officer, Is Leaving the Company Effective August 31 >AMED
Amedisys CIO Michael North Exits With $3M Severance Package
Amedisys' Contessa Health Selected to Participate in Medicare Alternative Payment Model for Dementia Patients
Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
Amedisys Cut to Hold From Buy by Deutsche Bank
Amedisys Price Target Maintained With a $101.00/Share by Deutsche Bank
Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101
Express News | Amedisys Inc : Deutsche Bank Cuts to Hold From Buy
Deutsche Bank Downgrades Amedisys to Hold From Buy, Price Target Is $101
TD Cowen Initiates Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
TD Cowen analyst Ryan Langston initiates coverage on $Amedisys(AMED.US)$ with a hold rating, and sets the target price at $101.According to TipRanks data, the analyst has a success rate of 90.0% and
Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
TD Cowen analyst Gary Taylor maintains $Amedisys(AMED.US)$ with a hold rating, and maintains the target price at $101.According to TipRanks data, the analyst has a success rate of 48.4% and a total
Amedisys | 10-Q: Q2 2024 Earnings Report
Amedisys (AMED) Gets a Hold From TD Cowen
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
Truist Financial analyst David S Macdonald maintains $Amedisys(AMED.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 63.2% and a total average return of 13.1%
Amedisys Non-GAAP EPS of $1.32 Beats by $0.14, Revenue of $591.2M Beats by $9.38M
Amedisys Releases Q2 Supplemental Financial Slides